Establishment Labs Holdings Inc. (3E0)
XMUN 
Summary
Establishment Labs: Procedure Economics Strengthens The Bull Case
Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics.
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs Q2 Earnings Call Highlights
Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.
Establishment Labs Holdings Inc. (3E0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Establishment Labs Holdings Inc. ever had a stock split?
Establishment Labs Holdings Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Fillipo Peter Caldini CEO | XMUN Exchange | VGG312491084 ISIN |
| US Country | 1,004 Employees | - Last Dividend | - Last Split | 19 Jul 2018 IPO Date |
Overview
Establishment Labs Holdings Inc. is a prominent medical technology company that has carved a niche for itself in the realm of aesthetic and reconstructive plastic surgery. Having been incorporated in 2004, the company is headquartered in Alajuela, Costa Rica. Over the years, Establishment Labs has dedicated itself to the manufacture and marketing of high-quality medical devices, focusing predominantly on innovations within the breast implant sector. Its products, underpinned by advanced technology, are designed to cater to the diverse needs of patients worldwide, aiming to enhance both aesthetic appeal and comfort. The company leverages a robust network of distributors and direct sales forces to deliver its solutions to physicians, hospitals, and clinics across key regions including Europe, the Middle East, Latin America, and Asia, thereby securing a significant position in the global medical aesthetic market.
Products and Services
- Motiva Implants
- Motiva Ergonomix and Motiva Ergonomix2
- Motiva Flora Tissue Expander
The flagship products of Establishment Labs, Motiva Implants, represent a line of silicone gel-filled breast implants renowned for their superior design and safety profiles. These implants are engineered to meet the varied aesthetic and reconstructive needs of patients, encapsulating the company's commitment to innovation and patient satisfaction.
Motiva Ergonomix and Motiva Ergonomix2 are specifically designed to mimic the natural movement of breast tissue, offering a gravity-sensitive option within the silicone gel-filled breast implants category. These products demonstrate Establishment Labs’ prowess in creating implants that provide a natural look and feel, thereby enhancing patient outcomes and comfort.
The Motiva Flora Tissue Expander is a surgical device intended for use in breast reconstruction procedures. It enables the gradual expansion of breast tissue, facilitating the subsequent insertion of a breast implant. This product underscores Establishment Labs’ contribution to the field of reconstructive surgery, offering innovative solutions that support patient recovery and aesthetic reconstruction.
